Core Insights - Qualigen Therapeutics, Inc. announced significant leadership and governance changes to enhance its executive team and financial transparency, supporting its strategic growth phase [1] Executive Appointments - Jerry (Jiawei) Wang appointed as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer effective October 2, 2025 [2] - Wang has a background as Global President and founding team member of Faraday Future, involved in raising over $3 billion and leading its IPO in 2021 [2] - Meka previously served as CFO of Faraday Future and has extensive experience at Ford Motor Company in finance roles [3] Board of Directors Expansion and Changes - Following a private placement on September 29, 2025, Qualigen's Board appointed three new members: Chad Chen, Kevin Chen, and Jay Sheng [4] - Jay Sheng has experience as Head of Operations & Finance Director at FF Global Partners LLC and previously served in a senior role at China Aviation Fuel [5] - Kevin Chen is Chief Economist and Chief Investment Officer at Horizon Financial, with board roles in multiple publicly listed companies [6] - Chad Chen is a partner at Yoka | Smith, LLP, with a focus on corporate litigation and business transactions [7] Resignations - Cody Price and Robert Lim resigned from the Board, and Campbell Becher stepped down as Director but remains President; all resignations were amicable [8][9] Auditor Transition - On October 3, 2025, Macias Gini & O'Connell LLP was engaged as the new independent auditor for the fiscal year ending December 31, 2025 [10] - WhitumSmith+Brown, PC resigned as Qualigen's auditor effective October 1, 2025, with no disagreements reported [11] Strategic Outlook - The leadership and governance changes are seen as a crucial step for Qualigen, positioning the company for long-term growth and shareholder value [12] - Qualigen focuses on developing innovative oncology and immunology therapeutics and is exploring crypto and web3 initiatives for global growth [12]